Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
European Journal of Nuclear Medicine and Molecular Imaging|May 8, 2020
Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapySimone Krebs, Joseph A O'Donoghue, Evan Biegel, et al.
Nuclear Medicine and Biology|May 26, 2019
A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticalsSai Kiran Sharma, Serge K Lyashchenko, Hijin A Park, et al.
EJNMMI Research|March 7, 2018
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinomaJorge A Carrasquillo, Joseph A O'Donoghue, Volkan Beylergil, et al.
Radiology|April 8, 2020
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human ImagingGary A Ulaner, Nicholas B Sobol, Joseph A O'Donoghue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide TetraxetanDiane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 9, 2025
Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy AnalysisRandy Yeh, Fresia Pareja, Parnian Shobeiri, et al.
Nuclear Medicine Communications|October 9, 2013
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancerVolkan Beylergil, Patrick G Morris, Peter M Smith-Jones, et al.
Radiology|June 10, 2020
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CTGary A Ulaner, Jorge A Carrasquillo, Christopher C Riedl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic CancerChristian Lohrmann, Eileen M O'Reilly, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2022
Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzumab PET: A Pilot StudyMelissa A Lumish, Steven B Maron, Viktoriya Paroder, et al.
Pageof 5